Pegsunercept

Pegsunercept
Clinical data
Routes of; administration	subcutaneous injection
Legal status
Legal status	investigational;
Pharmacokinetic data
Bioavailability	N/A
Identifiers
CAS Number	330988-75-5
ATC code	none
Chemical data
Formula	C502H758N154O165S16
Molar mass	12,103 g/mol (protein part)[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010^[update], Phase II clinical trials have been completed.^[1]^[2]^[3] It is being developed by Amgen.

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.^[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

40px	This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. v d e

↑ ClinicalTrials.gov NCT00037700 Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis
↑ ClinicalTrials.gov NCT00111423 Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
↑ ^3.0 ^3.1 Furst, DE; Fleischmann, R; Kopp, E; Schiff, M; Edwards C, 3rd; Solinger, A; Macri, M; 990136 Study, Group (2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of rheumatology. 32 (12): 2303–10. PMID 16331754. edit

Clinical data
Routes of administration	subcutaneous injection
Legal status
Legal status	investigational
Pharmacokinetic data
Bioavailability	N/A

Identifiers
CAS Number	330988-75-5
ATC code	none
Chemical data
Formula	C₅₀₂H₇₅₈N₁₅₄O₁₆₅S₁₆
Molar mass	12,103 g/mol (protein part)[[Script error: No such module "String".]]